AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.01 which represents a decrease of $-1.19 or -0.66% from the prior close of $179.2. The stock opened at $177.92 and touched a low of ...

This was the stock's second consecutive day of losses.

Chronic inflammation is a fundamental process implicated in the pathogenesis and progression of various complex immune ...

Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...

AbbVie Healthcare India Pvt. Ltd. found breaching UCPMP by sponsoring international trips for doctors, facing reprimand and ...

The stock's fall snapped a three-day winning streak.

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

( MENAFN - Baystreet) Issued on behalf of Oncolytics Biotech Inc.

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $180 which represents a slight increase of $1.61 or 0.90% from the prior close of $178.39. The stock opened at $178.41 and touched a low ...

Key players driving market growth include Pfizer Inc., Bristol Myers Squibb, Novartis, AbbVie, Abbott Laboratories, Roche Diagnostics, MD Anderson Cancer Center, Mayo Clinic, United Health Group, and ...

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, ...